Lung Cancer News and Research

Latest Lung Cancer News and Research

CINJ physicians named among 2012 list of U.S. News Top Doctors

Several physicians at The Cancer Institute of New Jersey (CINJ), who are faculty members at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, have been named as a 'Top Doctor' by U.S. News & World Report.

5 Oct 2012

Chronic kidney disease independently increases mortality risk

Findings from two meta-analyses published in The Lancet show that patients with chronic kidney disease are at high risk for death and end-stage renal disease even if they do not have comorbid hypertension or diabetes.

4 Oct 2012

Vulnerability to ‘thin ideal’ may be genetic

Results from a study carried out in identical and nonidentical twins suggests that a woman’s risk for thin-ideal internalization may be genetic.

4 Oct 2012

Routine screening influences outcomes in prostate cancer after surgery

Men who undergo radical prostatectomy for a tumor that was detected by screening show better long-term outcomes than their peers who undergo the surgery after opportunistic diagnosis, study results show.

3 Oct 2012

BMI concerns raised for childhood stem cell transplantation survivors

Childhood survivors of hematologic malignancies treated with allogeneic hematopoietic stem cell transplantation should undergo long-term monitoring of their body mass index and lean body mass, US researchers recommend.

3 Oct 2012

Synthetic hybrid molecules more effectively tackle chemo-resistant cancers

When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.

3 Oct 2012

Statins linked to reduced glaucoma risk

Cholesterol-lowering medications in the statin class could significantly reduce the risk for developing open-angle glaucoma, show data for more than 500,000 older-age US individuals with hyperlipidemia.

2 Oct 2012

Hormone and androgen receptor genes combined affect sperm motility

The combination of alleles for genes encoding the follicle-stimulating hormone receptor and androgen receptor has a significant impact on sperm motility, emphasising the importance of the genes in sperm quality, say Greek scientists.

1 Oct 2012

WBC counts in diabetes risk prediction

An elevated white blood cell count in young men is an independent predictor for the development of diabetes in later life, suggest study findings.

1 Oct 2012

Cholesterol has repercussions for recovering heroin addicts

Cholesterol levels may be negatively associated with heroin craving in patients on methadone maintenance therapy, researchers suggest.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012